Overview

  • Product name

    Entacapone, COMT inhibitor
  • Description

    Potent, selective, and reversible COMT inhibitor
  • Biological description

    Potent, selective, and reversible COMT inhibitor (IC50 = 151 nM). Inhibits α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis (IC50 = 100 μM). Potentiates L-dopa and attenuates associated motor fluctuations in vivo. Orally active.
  • Purity

    > 98%
  • CAS Number

    116314-67-1
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
  • Molecular weight

    305.29
  • Molecular formula

    C14H15N3O5
  • PubChem identifier

    4659568
  • Storage instructions

    Store at Room Temperature. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in DMSO to 100 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N
  • Source

    Synthetic

  • Research areas

References

This product has been referenced in:

  • Di Giovanni S  et al. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem 285:14941-54 (2010). Read more (PubMed: 20150427) »
  • Marin C & Obeso JA Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment. Int Rev Neurobiol 95:191-205 (2010). Read more (PubMed: 21095463) »
  • Marin C  et al. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol 192:184-93 (2005). Read more (PubMed: 15698633) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab142298.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up